The APOBEC1 (apolipoprotein B mRNA editing enzyme catalytic subunit 1) enzyme can then convert a cytidine base (C) to a uridine base (U) on the non-targeted strand of the DNA helix, creating a mismatched base pair [Ref 1]. The target-specific gRNA can guide the “dCas9-APOBEC” fusion to the targeted locus. The DNA repair machinery of the cell recognizes the mismatched base pair and replaces the U with T on the non-targeted strand and the A with a G base on the targeted strand, resulting in an A to G base change (Ref2, Ref3). The “dCas9-APOBEC” fusion system provides a powerful genomic base editing tool for single-nucleotide changes.
This premade lentivirus express the dCa9-APOBEC1 fusion under the enhanced CMV promoter (SuCMV), carrying Blasticidin selection.
If desired, the negative control lentivirus, CAT#: LVP1595, which has the dCas9 fusioned with a Null sequence, can be used as the non-specific, background control.
To edit your desired sequence, simply apply this lentivirus to your cells and then add the targeting gRNA lentivirus (which need to be designed and made separately according to your target locus.), or apply this lentivirus together with your desired gRNA lentivirus. (Note: Contact us if you need to make your desired gRNA lentivirus via a customized order).
see details in Product Manual.
Amount: 200 ul/vial, at titer of 1×108 IFU/ml, provided in PBS solution (premixed with 10x polybrene, 60 ug/ml).